Danielle Valletti, Assistant Editor

Embedded pharmacy experts in neurology strengthen multiple sclerosis care through education, therapy selection, lab monitoring, and collaborative practice agreements that close gaps.

Explore how pharmacists can support pancreatic cancer patients on atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for pancreatic cancer patients.

Pharmacists learn how protective purchasing impacts drug shortages and discover strategies to enhance supply chain visibility and patient access to essential medications.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Innovative biodegradable nanoplatforms enhance cancer therapy by integrating targeted drug delivery and real-time imaging, revolutionizing oncology practices for pharmacists.

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.

Zavabresib receives orphan drug designation for myelofibrosis, offering hope for patients unresponsive to current treatments and enhancing therapeutic options.

Discover groundbreaking FDA-approved treatments, including at-home depression therapy, new biosimilars, and culturally relevant pain relief options.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

Pharmacists play a vital role in identifying and managing primary immunodeficiency diseases, enhancing patient outcomes through immunoglobulin therapy and education.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

Pharmacists play a vital role in supporting multiple sclerosis patients by addressing medication challenges, educating on treatments, and navigating insurance hurdles.

Explore how pharmacists enhance access to care for multiple sclerosis patients, tackling barriers in diagnosis, treatment, and patient education.

The FDA expands Cerezyme's approval for treating non-CNS symptoms of type 3 Gaucher disease, marking a significant advancement in patient care.

Pharmacists play a crucial role in educating patients with multiple sclerosis about treatment options, adverse effects, and navigating insurance challenges.

FDA's draft guidance on MRD and CR as end points accelerates multiple myeloma therapy approvals, enhancing patient access and transforming oncology practices.

Innovative immunotherapy strategies, like linvoseltamab, show promise in treating multiple myeloma, potentially reducing reliance on traditional transplants.

Pharmacists enhance care for multiple sclerosis patients by improving access, education, and adherence, ensuring effective treatment through collaboration with healthcare teams.

Explore the evolving landscape of myelofibrosis treatment, focusing on personalized therapy, JAK inhibitors, and the role of pharmacists in patient care.

Jordan Harper, DMD, discusses innovative fluoride-free toothpaste tablets with hydroxyapatite, offering effective oral care solutions for all patients.

FDA grants Priority Review for gedatolisib, a promising treatment for advanced HR+/HER2- breast cancer, showcasing significant efficacy in recent trials.

Discover how hydroxyapatite toothpaste tablets revolutionize oral care with eco-friendly, effective, and gentle alternatives to traditional fluoride toothpaste.

New research reveals circulating tumor cells can predict patient response to tarlatamab in small cell lung cancer, enhancing personalized treatment strategies.

Discover how ENAMEL revolutionizes oral care with eco-friendly, waterless toothpaste tablets made from clean, natural ingredients.

New research reveals PUF60's critical role in triple-negative breast cancer, highlighting RNA splicing as a promising therapeutic target for oncology.